U.S. markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.9200+0.1500 (+3.14%)
At close: 04:00PM EST

Poseida Therapeutics, Inc.

9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100

Full Time Employees304

Key Executives

NameTitlePayExercisedYear Born
Dr. Eric M. Ostertag M.D., Ph.D.Exec. Chairman667.42kN/A1973
Mr. Mark J. Gergen J.D.CEO & Director659.53kN/A1963
Ms. Johanna M. Mylet CPAChief Financial OfficerN/AN/A1987
Mr. Loren WagnerSr. VP of Global OperationsN/AN/AN/A
Dr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell TherapyN/AN/AN/A
Ms. Kristin MartinChief People & Admin. OfficerN/AN/AN/A
Sarah ThailingSr. Director of Corp. Communications & IRN/AN/AN/A
Mr. Harry J. Leonhardt Esq., J.D.Gen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1957
Ms. Lisa PortaleSr. VP of Regulatory AffairsN/AN/AN/A
Mr. Brent WarnerPres of Gene TherapyN/AN/A1984
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Corporate Governance

Poseida Therapeutics, Inc.’s ISS Governance QualityScore as of November 28, 2022 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.